"The discussant at the Clinical Science Symposium on PD1/PDL1 pathway immunotherapy, Dr. Walter Urba of the Providence Cancer Center (Portland, OR), summed up the stunning progress that has been made in immunotherapy for melanoma with the bold statement that “immunotherapy is now the first-line treatment for metastatic melanoma regardless of mutation status.”"
June 9, 2013
ASCO: Immunotherapy for Advanced Melanoma
ASCO: Immunotherapy for Advanced Melanoma by Susan Beck, Executive Editor, ONCOLOGY. Subscription may be required to read the article.